Eli Lilly faces Q1 sales headwinds as incretin gains offset by weakness in other drugs

May 1, 2025 4:00 AM

Eli Lilly and Co. may face a challenging first quarter, with analysts at Wells Fargo Securities projecting a potential 2 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found